Bill

Bill > HR3520


US HR3520

US HR3520
STAND Against Emerging Opioids Act Scheduling Tianeptine and Analogues Now to Defend Against Emerging Opioids Act


summary

Introduced
05/20/2025
In Committee
05/20/2025
Crossed Over
Passed
Dead

Introduced Session

119th Congress

Bill Summary

A BILL To amend the Controlled Substances Act to provide for the scheduling of tianeptine as a schedule III substance, and for other purposes.

AI Summary

This bill aims to add tianeptine and its related chemical variants to Schedule III of the Controlled Substances Act, which means the drug will be classified as a controlled substance with potential for abuse and accepted medical use. Tianeptine is an antidepressant drug originally developed in France that has gained attention for its potential opioid-like effects and risk of addiction. By scheduling tianeptine, the bill seeks to regulate its production, distribution, and possession at the federal level. The legislation specifies that the scheduling will take effect 90 days after the bill's enactment, and it covers not just the primary substance but also its analogues (chemically similar compounds), salts, isomers, and salts of isomers. The bill's full name, the "STAND Against Emerging Opioids Act," reflects its intent to address emerging drug threats and prevent potential misuse of substances with opioid-like properties.

Committee Categories

Business and Industry

Sponsors (3)

Last Action

Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (on 05/20/2025)

bill text


bill summary

Loading...

bill summary

Loading...
Loading...